Latest news with #APA
Hans India
a day ago
- Business
- Hans India
Best Website for Assignment Help Globally to Get Assignment Done Online
There are many assignment help services where you can hire professional assignment helpers online. However, is the best and most reliable 100% human written assignments across the USA, UK, Canada and Australia. In fact, is the only assignment help service that helps college, master and doctoral students with assignments with real experts located within the USA and not remote writers from elsewhere in the world. The best benefit of asking Coursepivot assignment helpers to do your assignment is that you get professionally done assignments by ENL writers from the USA. This is a US-based company with headquarters and offices in Texas, USA. Coursepivot has satellite offices in Canada, UK, and Australia as well, which means they offer their homework and assignment help services to students across the globe. If you are within Europe, maybe Spain, Ireland, or Germany, is a reliable assignment helper today. If you are a student in the Middle East or Asia, Coursepivot has professional assignment helpers for international students like you. The Best Assignment Help Services, Coursepivot, Rated the Best by Master and PHD Students – Rated 97/100 by students – Best assignment help service to ask someone to do your assignments online without using AI and without plagiarism within the USA and globally. to ask someone to do your assignments online without using AI and without plagiarism within the USA and globally. – Rated 95/100 – Cheap homework help service for students who need help with custom essays and term papers. If you are saying, I want to pay someone to write my APA essay, or complete my term paper in MLA, Chicago, Turabian, or Harvard, Coursepivot is absolutely the most reliable homework help service in the world today. Why Pay Someone to Do my Assignment for Me – Top 5 Benefits for You 100% AI-Free and Human-Written Work: Every assignment is written by real U.S.-based experts—no AI tools, no shortcuts. You'll receive work that's undetectable by Turnitin AI checkers. Zero Plagiarism Guarantee: Each paper is crafted from scratch, with a free originality report provided. You can confidently submit your thesis, dissertation, or essay without fear. Save Time for Other Priorities: Let Coursepivot handle your complex assignments while you focus on internships, exams, or personal life—without missing deadlines. Subject-Specific Experts at Every Level: Get matched with master's and PhD-level experts in MBA, psychology, nursing, management, public health, and more—writing that meets academic rigor. Formatted to Perfection: Every assignment includes proper referencing (APA, MLA, Harvard, Chicago, etc.), a free cover page, and a reference list—ready to submit. Thousands of students trust today because we deliver expertly written, 100% human-crafted assignments in high-demand fields like MBA, Nursing, Marketing, Psychology, Management, Business, and Education. From regular homework and research essays to complex capstone projects, master's theses, and doctoral dissertations, students rely on our U.S.-based academic professionals for quality, originality, and confidentiality. With AI-free content, zero plagiarism, and fast turnaround—even on urgent deadlines—Coursepivot has become the most reliable assignment help service trusted by college and graduate students worldwide. So, is Coursepivot a reliable essay writing service? Yes, university students—especially in the USA—can fully trust Coursepivot. As a U.S.-based academic college paper writing service with real American assignment writers, Coursepivot guarantees 100% AI-free, plagiarism-free assignments tailored to U.S. university standards. ' saved my GPA during my final MBA semester. I needed someone reliable to write my marketing capstone project, and they delivered a completely original, well-researched paper ahead of deadline. No AI, no plagiarism—just real expertise. I wouldn't trust anyone else with my assignments.'— Samantha R., MBA Student, Texas. Assignment Help Services to Pay for on Coursepivot, the Best Homework Help Service in the World Assignment Help Category Why Coursepivot is the Best Nursing Assignment Help Coursepivot has U.S.-based nursing experts who deliver clinical accuracy and originality. Marketing Assignment Writing Service Professional marketing writers craft AI-free essays, plans, and case studies. Psychology Assignment Help Expert psychology writers deliver APA-compliant, research-driven assignments. MBA Assignment Help MBA thesis, dissertations, and capstones written by business graduate professionals. University Assignments Reliable help for all college subjects with real U.S.-based experts. Thesis Help Master's-level theses written from scratch, tailored to your field and format. Dissertation Help PhD experts complete complex dissertations with academic precision. Management Assignment Help Business and HR management papers handled by top-tier writers. History Homework Help Healthcare and Public Health Assignments Historically accurate, well-referenced assignments written by humanities experts. U.S.-trained public health experts ensure evidence-based, AI-free content. Students trust Coursepivot because it consistently delivers high-quality, original, and AI-free assignments written by real U.S.-based academic experts. From MBA and nursing to psychology, public health, and thesis writing, Coursepivot guarantees plagiarism-free work tailored to each student's exact instructions and academic level. With a reputation for on-time delivery, expert support, and confidentiality, Coursepivot has become the go-to platform for college, graduate, and international students seeking reliable assignment help they can count on. Survey on Which Website is Most Trusted by Students to Do Assignments Online A survey conducted in April 2025 asked 2,000 university and graduate students across the USA, UK, Canada, Australia, and other regions to name the most trusted assignment help service. The goal was to identify which platform students prefer for essays, term papers, thesis, dissertations, and subject-specific assignments. emerged as the clear favorite, earning 74% of the total votes—making it the most trusted assignment helper in the world. Competing platforms like and received only 12% and 6% respectively. What stood out most in the results was that over 60% of the students who selected Coursepivot were Master's and PhD students based in the USA. These students highlighted Coursepivot's U.S.-based expert writers, plagiarism-free content, AI-free policy, and consistent academic quality as reasons they rely on it. In short, Coursepivot is the go-to assignment help service for serious students, especially those pursuing advanced degrees who need trustworthy, original, and academically sound support. 👉 Want to check out Coursepivot website: Do my Assignment for Me Assignment Help Service Frequently Asked Questions Is Coursepivot a Reliable Assignment Helper Yes, is one of the most trusted assignment help services globally. It is U.S.-based, employs only native English-speaking writers, and guarantees 100% original, AI-free, and plagiarism-free content. From essays and research papers to master's theses and doctoral dissertations, Coursepivot delivers high-quality academic work that meets strict university standards. Can I Pay Someone to Write My Assignment for Me? Absolutely. It is completely acceptable to pay someone to write your assignment online—especially through a professional academic service like Whether you're struggling with a tough deadline, a complex subject like MBA, nursing, or psychology, or just need extra support, Coursepivot allows you to hire expert U.S.-based writers who will craft your paper from scratch. Which Is Overall the Best Assignment Help Service in the World Today? is currently rated as the best assignment help service in the world by both undergraduate and graduate students. Known for its U.S.-based experts, strict no-AI policy, plagiarism-free guarantee, and affordable pricing, Coursepivot is the most recommended platform for students in the USA, UK, Canada, and beyond seeking reliable and professional academic writing support.
Time Business News
2 days ago
- Politics
- Time Business News
The Dual Oversight of Power: Executive and Legislative Control in U.S. Administration
By Jean Richard Franck, M.A., Doctoral Student in Public Administration In the landscape of American democracy, power does not reside in a single person, branch, or institution. It is checked, balanced, and most importantly—shared. Nowhere is this more evident than in the oversight of administrative agencies, where both the executive and legislative branches exercise authority. This shared control is not a tug-of-war. It is a dynamic process—a choreography of law, leadership, and legitimacy. Many people imagine that the President alone controls the agencies of government. After all, the President appoints agency heads, signs executive orders, and shapes the national agenda. But in truth, Congress is the architect. It creates these agencies, defines their scope, and holds the purse strings. One branch steers the ship, the other builds and funds it. Together, they guide the course of governance. Consider the President's tools: executive orders, budget proposals, memoranda, and the authority to nominate (and in some cases, remove) key officials. These powers are formidable. They allow the President to implement change without waiting for legislation. Through the Office of Information and Regulatory Affairs (OIRA), the President can even delay or revise agency regulations that don't align with White House priorities. Yet this power, though wide, is not absolute. It is rooted in constitutional and statutory law. Article II of the Constitution vests executive power in the President, and charges him with the faithful execution of the law. That duty sets boundaries. The President cannot legislate, only implement. And while the courts can challenge executive overreach, it is Congress that provides the long-term counterbalance. Congress shapes the administrative state through structural design, delegation, funding, and oversight. It decides which agencies exist, what they do, and how their decisions must be made. The Administrative Procedure Act (APA), a cornerstone of modern governance, is a legislative act that mandates transparency, fairness, and public participation in agency rulemaking. Congress doesn't merely create law—it ensures the law is applied as intended. The difference in how these two branches exercise power is profound. The executive acts swiftly. The legislative acts deliberately. The President commands from the center. Congress deliberates through committees and coalitions. One responds to crises with urgency; the other reflects the consensus of a nation. This tension is not dysfunction—it's design. We've seen this interplay throughout history. Presidents have issued bold executive orders to drive environmental policy, economic reform, and public health action. Meanwhile, Congress has investigated those same agencies, reined in budgets, and rewritten authorizing statutes. Sometimes they clash. Sometimes they collaborate. But the system endures, because the balance itself is a form of accountability. As a student of public administration, I see this dual oversight as more than a procedural function. It is a reminder that no one governs alone. Our institutions are complex by intention, not by accident. They are layered, not to confuse, but to protect. Governance in a democracy must be resilient—not only against inefficiency, but against unchecked power. So the next time we read about a regulatory agency drafting a rule, pausing a program, or changing a standard, we should remember: that action is not the product of one decision, but of many. It is the result of oversight, vision, and law—shaped by both executive leadership and legislative design. In that duality, we find the essence of American public administration: governance that is powerful, but never singular. Accountable, but never isolated. Structured, but never static. Jean Richard Franck, M.A. Doctoral Student in Public Administration Writer | Policy Analyst | Advocate for Ethical and Accountable Government TIME BUSINESS NEWS
Cision Canada
3 days ago
- Business
- Cision Canada
BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA")
The APA Formalized the February 2024 BioVaxys Acquisition of the Former IMV Inc. Assets VANCOUVER, BC , May 29, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce today that the Company and Horizon Technology Finance Corporation ("Horizon") have executed a follow-on Amendment ("Amendment") to the Asset Purchase Agreement dated February 11th, 2024 ("APA") for acquiring the entire portfolio of assets and intellectual property based on the DPX™ immune educating platform technology developed by Canadian biotechnology company, IMV Inc. Section 12 of the February 11 th, 2024 APA is a performance milestone provision for BioVaxys to demonstrate an aggregate capital raise of USD $10M by December 31 , 2024. On December 9 th, 2024, Horizon and BioVaxys initially amended the APA by agreeing to delete the reference to " December 31, 2024 " found in Section 12 and replacing it with the date of " June 30, 2025 ." This new Amendment of May 29 th, 2025, supersedes and replaces the Section 12 terms of the APA so that the net performance milestone required to be raised in any form (including, but not limited to equity, grants, licensing fees, or loans) is now significantly lowered to USD $2,028,636 . If BioVaxys is successful in meeting this milestone by September 30, 2025 , Section 12 of the APA shall end and be of no further force or effect. As consideration for Horizon amending the APA, BioVaxys agrees to issue to Horizon 2,800,000 share purchase warrants and 1,200,000 share purchase warrants to Powerscourt Investments XXV LP ("Powerscourt"), with each warrant entitling Horizon and Powercourt the purchase of one whole at a purchase price of $0.06 Canadian Dollars per share at any time on or before May 31 , 2028. Horizon and Powerscourt are the members/owners of HIMV LLC (70%/30%), the party to the APA. All other terms and conditions of the APA to remain the same. BioVaxys and Horizon have further agreed that Section 7(c)(i) of the APA "Licensing Earn-Out Payments Term" be amended from the original "Eighth anniversary of the Closing Date" found in the last line of Section 7(c)(i) to August 11, 2033. During the Licensing Non-Sales Earn-Out Term, BioVaxys shares a predetermined percentage of net licensing non-sales revenues with Horizon. The "Licensing Non-Sales Earn-Out Term" refers to payments received from an existing licensee or preexisting potential licensee, ending upon the expiration of the last valid claim of a former IMV patent that is the subject of the license agreement to which such existing licensee or preexisting potential licensee is party, and any other payment received under a license agreement, ending on August 11, 2033 . About BioVaxys Technology Corp. BioVaxys Technology Corp. ( is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on its DPX™ immune-educating technology platform and its HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated and unique mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, and DPX+rPA for peanut allergy prophylaxis, as well as several viral vaccines. BioVaxys has licensed its patented liposome-based delivery platform to Zoetis, Inc. and SpayVac-for-Wildlife, Inc. for selected animal health applications. BioVaxys common shares are listed on the CSE under the stock symbol 'BIOV', trade on the Frankfurt Bourse (FRA: 5LB), and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed " James Passin " James Passin , Chief Executive Officer Phone: +1 740 358 0555 Cautionary Statements Regarding Forward Looking Information This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Investors are encouraged to read BioVaxys continuous disclosure documents and audited annual consolidated financial statements which are available on SEDAR at Logo - SOURCE BioVaxys Technology Corp.
Yahoo
3 days ago
- Business
- Yahoo
BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA")
The APA Formalized the February 2024 BioVaxys Acquisition of the Former IMV Inc. Assets VANCOUVER, BC, May 29, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce today that the Company and Horizon Technology Finance Corporation ("Horizon") have executed a follow-on Amendment ("Amendment") to the Asset Purchase Agreement dated February 11th, 2024 ("APA") for acquiring the entire portfolio of assets and intellectual property based on the DPX™ immune educating platform technology developed by Canadian biotechnology company, IMV Inc. Section 12 of the February 11th, 2024 APA is a performance milestone provision for BioVaxys to demonstrate an aggregate capital raise of USD $10M by December 31, 2024. On December 9th, 2024, Horizon and BioVaxys initially amended the APA by agreeing to delete the reference to "December 31, 2024" found in Section 12 and replacing it with the date of "June 30, 2025." This new Amendment of May 29th, 2025, supersedes and replaces the Section 12 terms of the APA so that the net performance milestone required to be raised in any form (including, but not limited to equity, grants, licensing fees, or loans) is now significantly lowered to USD $2,028,636. If BioVaxys is successful in meeting this milestone by September 30, 2025, Section 12 of the APA shall end and be of no further force or effect. As consideration for Horizon amending the APA, BioVaxys agrees to issue to Horizon 2,800,000 share purchase warrants and 1,200,000 share purchase warrants to Powerscourt Investments XXV LP ("Powerscourt"), with each warrant entitling Horizon and Powercourt the purchase of one whole at a purchase price of $0.06 Canadian Dollars per share at any time on or before May 31, 2028. Horizon and Powerscourt are the members/owners of HIMV LLC (70%/30%), the party to the APA. All other terms and conditions of the APA to remain the same. BioVaxys and Horizon have further agreed that Section 7(c)(i) of the APA "Licensing Earn-Out Payments Term" be amended from the original "Eighth anniversary of the Closing Date" found in the last line of Section 7(c)(i) to August 11, 2033. During the Licensing Non-Sales Earn-Out Term, BioVaxys shares a predetermined percentage of net licensing non-sales revenues with Horizon. The "Licensing Non-Sales Earn-Out Term" refers to payments received from an existing licensee or preexisting potential licensee, ending upon the expiration of the last valid claim of a former IMV patent that is the subject of the license agreement to which such existing licensee or preexisting potential licensee is party, and any other payment received under a license agreement, ending on August 11, 2033. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on its DPX™ immune-educating technology platform and its HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated and unique mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, and DPX+rPA for peanut allergy prophylaxis, as well as several viral vaccines. BioVaxys has licensed its patented liposome-based delivery platform to Zoetis, Inc. and SpayVac-for-Wildlife, Inc. for selected animal health applications. BioVaxys common shares are listed on the CSE under the stock symbol 'BIOV', trade on the Frankfurt Bourse (FRA: 5LB), and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed "James Passin" James Passin, Chief Executive OfficerPhone: +1 740 358 0555 Cautionary Statements Regarding Forward Looking Information This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Investors are encouraged to read BioVaxys continuous disclosure documents and audited annual consolidated financial statements which are available on SEDAR at Logo - View original content to download multimedia: SOURCE BioVaxys Technology Corp. Sign in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
Baltimore drops lawsuit challenging efforts to defund CFPB
The city of Baltimore on Thursday voluntarily dismissed its lawsuit challenging the Trump administration's efforts to defund the Consumer Financial Protection Bureau (CFPB). The city, which is represented by the left-leaning legal organization Democracy Forward, cited the government's position in court that it won't transfer money from its reserve fund to dismantle the independent agency as reason for dropping the case. 'Defendants have repeatedly represented that there is no mechanism by which Defendant Consumer Financial Protection Bureau can transfer away money from, or otherwise relinquish control over the money in, the Bureau Fund,' lawyer Mark Samburg wrote in the filing, provided first to The Hill. Samburg said the city and Economic Action Maryland Fund, the other plaintiff in the lawsuit, would 'undertake further actions as appropriate' if the administration later contradicts its position. Since February, the government has acknowledged in court filings that returning CFPB's funds to the Federal Reserve would not be possible. Both CFPB Chief Financial Officer Ngagne Jafnar Gueye and Chief Operating Officer Adam Martinez said in declarations that they were not aware of any mechanism that would make such a transfer possible. Martinez said in his March declaration that Gueye looked into the matter and concluded that 'there is indeed no authority or mechanism to transfer excess funds back to the Federal Reserve, to transfer excess funds to the Federal Reserve's control, or to transfer excess funds to the control of any other entity.' 'The agency has therefore not attempted to do so,' the COO said. U.S. District Judge Matthew Maddox, who is overseeing the case, previously denied Baltimore's request for a temporary restraining order after finding that the challengers failed to prove the administration took a 'final agency action' to defund the consumer watchdog, which is mandatory for relief in claims brought under the Administrative Procedure Act (APA). The Trump administration filed a motion to dismiss the case earlier this month. Skye Perryman, president and CEO of Democracy Forward, called the case a 'big win for consumers.' 'Our case derailed Russ Vought's plan to defund the CFPB — an agency that has been a critical defender of American consumers,' Skye Perryman said. Baltimore and Economic Action Maryland Fund sued the CFPB and Russell Vought, its acting director, earlier this year, claiming that by seeking to return its reserve funds to the Federal Reserve or Treasury Department they effectively sought to defund and defang the agency. The CFPB was an early target of the Trump administration and the Department of Government Efficiency (DOGE). In a separate lawsuit, a federal judge enjoined the administration from dismantling the CFPB. A federal appeals court then issued an order that was construed as greenlighting major cuts at the agency, but it later partially lifted that decision and has not yet ruled on the merits. 'While the administration continues its efforts to dismantle the CFPB and weaken regulations that protect people from fraud and debt traps, we are delighted that the government concedes it cannot defund the bureau by transferring money from its reserve fund,' Marceline White, executive director of Economic Action Maryland Fund, said in a statement. 'This is a win for ordinary folks and we were proud to work with Democracy Forward and the City of Baltimore to stop this effort.' Updated at 1:28 p.m. EDT Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
